Lexatumumab


Lexatumumab is an experimental agonistic human monoclonal antibody against TRAIL-R2, intended for the treatment of cancer.
HGS-ETR2 antibodies were generated by Human Genome Sciences through a collaboration with Cambridge Antibody Technology.
Development was discontinued in 2015.